An official website of the United States government
Establish a searchable, open access research database that contains all clinical, biomarker, and epidemiological data, and related genotypes and phenotypes from existing genetic studies; analyze these data to identify regions of the genome that are targets for AD and ADRD therapeutics.
2017 RFA-AG-18-014: Limited Competition: Data Coordinating Center for the Accelerating Medicines Partnership Target Discovery and Preclinical Validation Consortium AMP AD DCC (U24- Clinical Trial Not Allowed) PAR-16-047: National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (U24) PAR-20-110: National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (U24 Clinical Trial Not Allowed) RFA-AG-25-015: Coordination Center for the Alzheimer’s Disease Sequencing Project Consortium (U01 Clinical Trial Not Allowed) 6.A Achieved Establish a searchable, open access research database that contains all clinical, biomarker, and epidemiological data, and related genotypes and phenotypes from existing genetic studies… DN 2012 AD Summit: 1C Blog: Increasing the usability of big data for Alzheimer’s research Blog: Open the portal door to Alzheimer’s Big Data Blog: NIAGADS! We have data! Blog: Open science delivers a wealth of AD/ADRD research data to a portal near you Workshop: Alzheimer’s Disease Genetics Global Symposium: Pathway to Translation Drug Development - Novel Targets Agora NIA Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) NIAGADS Genomics Database 2013
- At least one novel target, pathway or therapeutic approach identified through use of the database.
Summary of Key Accomplishments
Through a series of targeted funding initiatives, NIA established and continues to support the NIA Alzheimer's Disease Data Storage Site (NIAGADS) as the national genetics repository. NIAGADS provides high quality genetic and genomic data for the study of the complex genetics of late-onset Alzheimer's disease.
NIAGADS currently hosts genetic data from over 30,000 individuals with AD, other dementias of aging and cognitively normal individuals. The genetic discoveries to date have led to the identification of multiple disease pathways and genes that are being pursued as drug targets for AD (e.g., TREM2, PU.1, PLCG2 and INPP5D).
The key accomplishments summary is current as of March 2022.